CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Canakinumab 150 MG/ML [Ilaris]Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.07

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia

The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.

NCT04348448 COVID-19 Drug: Canakinumab 150 MG/ML [Ilaris]

Primary Outcomes

Description: percentage of patients treated with canakinumab sc who do not require intensive care treatment during hospitalization for COVID-19

Measure: intensive care treatment

Time: 9 months

Secondary Outcomes

Description: ICU stay times

Measure: ICU stay times

Time: 9 months

Description: percentage of patients who died 1 month after treatment

Measure: % died after 1 month after treatment

Time: 9 months

Description: time of hospitalization

Measure: hospitalization

Time: 9 months

Description: number of adverse event

Measure: adverse event

Time: 9 months

Related HPO nodes (Using clinical trials)